Increlex IGF-1 just approved in Canada
NEWS PROVIDED BY
Ipsen Biopharmaceuticals
MISSISSAUGA, ON, March 16, 2021 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD), following its Health Canada approval in December 1, 2020
It’s been around forever and they just made it available!!? Smh .
Max